Research programme: peptide-based radiopharmaceuticals - Fusion Pharmaceuticals/48Hour Discovery

Alternative Names: Research programme: peptide-based radiopharmaceuticals - 48Hour Discovery/Fusion Pharmaceuticals

Latest Information Update: 10 Jun 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 48Hour Discovery; Fusion Pharmaceuticals
Class Antineoplastics; Peptide drug conjugates; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
11 Jan 2022 Fusion Pharmaceuticals enters into collaboration agreement with 48 Hour Discovery for peptide-based radiopharmaceuticals
11 Jan 2022 Early research in Solid tumours in Canada (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com